FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3177576621> ?p ?o ?g. }

• W3177576621 endingPage "571" @default.
• W3177576621 startingPage "555" @default.
• W3177576621 abstract "Doxorubicin (DOX) is a cornerstone drug in the treatment of osteosarcoma. However, achieving sufficient concentration in the tumor tissue after systemic administration with few side effects has been a challenge. Even with the most advanced nanotechnology approaches, less than 5% of the total administered drug gets delivered to the target site. Alternatives to increase the local concentration of DOX within the tumor using improved drug delivery methods are needed. In this study, we evaluate a clinically approved calcium sulfate/hydroxyapatite (CaS/HA) carrier, both in-vitro and in-vivo, for local, sustained and controlled delivery of DOX to improve osteosarcoma treatment. In-vitro drug release studies indicated that nearly 28% and 36% of the loaded drug was released over a period of 4-weeks at physiological pH (7.4) and acidic pH (5), respectively. About 63% of the drug had been released after 4-weeks in-vivo. The efficacy of the released drug from the CaS/HA material was verified on two human osteosarcoma cell lines MG-63 and 143B. It was demonstrated that the released drug fractions functioned the same way as the free drug without impacting its efficacy. Finally, the carrier system with DOX was assessed using two clinically relevant human osteosarcoma xenograft models. Compared to no treatment or the clinical standard of care with systemic DOX administration, the delivery of DOX using a CaS/HA biomaterial could significantly hinder tumor progression by inhibiting angiogenesis and cell proliferation. Our results indicate that a clinically approved CaS/HA biomaterial containing cytostatics could potentially be used for the local treatment of osteosarcoma. The triad of doxorubicin (DOX), methotrexate and cisplatin has routinely been used for the treatment of osteosarcoma. These drugs dramatically improved the prognosis, but 45-55% of the patients respond poorly to the treatment with low 5-year survival. In the present study, we repurpose the cornerstone drug DOX by embedding it in a calcium sulfate/hydroxyapatite (CaS/HA) biomaterial, ensuring a spatio-temporal drug release and a hypothetically higher and longer lasting intra-tumoral concentration of DOX. This delivery system could dramatically hinder the progression of a highly aggressive osteosarcoma compared to systemic administration, by inhibiting angiogenesis and cell proliferation. Our data show an efficient method for supplementary osteosarcoma treatment with possible rapid translational potential due to clinically approved constituents." @default.
• W3177576621 created "2021-07-19" @default.
• W3177576621 creator A5016239771 @default.
• W3177576621 creator A5023363049 @default.
• W3177576621 creator A5032111744 @default.
• W3177576621 creator A5048120380 @default.
• W3177576621 creator A5065469628 @default.
• W3177576621 creator A5074735538 @default.
• W3177576621 creator A5079512662 @default.
• W3177576621 creator A5091036064 @default.
• W3177576621 date "2021-09-01" @default.
• W3177576621 modified "2023-09-23" @default.
• W3177576621 title "Sustained and controlled delivery of doxorubicin from an in-situ setting biphasic hydroxyapatite carrier for local treatment of a highly proliferative human osteosarcoma" @default.
• W3177576621 cites W1485330998 @default.
• W3177576621 cites W1589920570 @default.
• W3177576621 cites W1706026279 @default.
• W3177576621 cites W1981316500 @default.
• W3177576621 cites W1984224798 @default.
• W3177576621 cites W1992734050 @default.
• W3177576621 cites W1995602602 @default.
• W3177576621 cites W1999914295 @default.
• W3177576621 cites W2009727781 @default.
• W3177576621 cites W2018613635 @default.
• W3177576621 cites W2021635812 @default.
• W3177576621 cites W2027147390 @default.
• W3177576621 cites W2027602981 @default.
• W3177576621 cites W2041732192 @default.
• W3177576621 cites W2041936982 @default.
• W3177576621 cites W2046737348 @default.
• W3177576621 cites W2055073285 @default.
• W3177576621 cites W2065001970 @default.
• W3177576621 cites W2067213531 @default.
• W3177576621 cites W2070003597 @default.
• W3177576621 cites W2070081046 @default.
• W3177576621 cites W2073109541 @default.
• W3177576621 cites W2080504953 @default.
• W3177576621 cites W2087146189 @default.
• W3177576621 cites W2090106748 @default.
• W3177576621 cites W2091799331 @default.
• W3177576621 cites W2092665512 @default.
• W3177576621 cites W2105746478 @default.
• W3177576621 cites W2112573917 @default.
• W3177576621 cites W2115749410 @default.
• W3177576621 cites W2116925334 @default.
• W3177576621 cites W2118783447 @default.
• W3177576621 cites W2148226658 @default.
• W3177576621 cites W2155127143 @default.
• W3177576621 cites W2165836181 @default.
• W3177576621 cites W2171987859 @default.
• W3177576621 cites W2317833459 @default.
• W3177576621 cites W2321567914 @default.
• W3177576621 cites W2329218644 @default.
• W3177576621 cites W2344644350 @default.
• W3177576621 cites W2396893196 @default.
• W3177576621 cites W2409618684 @default.
• W3177576621 cites W2507804087 @default.
• W3177576621 cites W2509593593 @default.
• W3177576621 cites W2525938729 @default.
• W3177576621 cites W2551072835 @default.
• W3177576621 cites W2554451310 @default.
• W3177576621 cites W2566181309 @default.
• W3177576621 cites W2567776014 @default.
• W3177576621 cites W2620057650 @default.
• W3177576621 cites W2766149272 @default.
• W3177576621 cites W2792308604 @default.
• W3177576621 cites W2807241802 @default.
• W3177576621 cites W2888649794 @default.
• W3177576621 cites W2908684418 @default.
• W3177576621 cites W2916952896 @default.
• W3177576621 cites W2947994624 @default.
• W3177576621 cites W2956905292 @default.
• W3177576621 cites W2983881420 @default.
• W3177576621 cites W2987507230 @default.
• W3177576621 cites W2992292488 @default.
• W3177576621 cites W3009193015 @default.
• W3177576621 cites W3040891077 @default.
• W3177576621 cites W3040975431 @default.
• W3177576621 cites W3046718334 @default.
• W3177576621 cites W3135286045 @default.
• W3177576621 cites W4235565063 @default.
• W3177576621 doi "https://doi.org/10.1016/j.actbio.2021.07.016" @default.
• W3177576621 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34271171" @default.
• W3177576621 hasPublicationYear "2021" @default.
• W3177576621 type Work @default.
• W3177576621 sameAs 3177576621 @default.
• W3177576621 citedByCount "25" @default.
• W3177576621 countsByYear W31775766212022 @default.
• W3177576621 countsByYear W31775766212023 @default.
• W3177576621 crossrefType "journal-article" @default.
• W3177576621 hasAuthorship W3177576621A5016239771 @default.
• W3177576621 hasAuthorship W3177576621A5023363049 @default.
• W3177576621 hasAuthorship W3177576621A5032111744 @default.
• W3177576621 hasAuthorship W3177576621A5048120380 @default.
• W3177576621 hasAuthorship W3177576621A5065469628 @default.
• W3177576621 hasAuthorship W3177576621A5074735538 @default.
• W3177576621 hasAuthorship W3177576621A5079512662 @default.
• W3177576621 hasAuthorship W3177576621A5091036064 @default.
• W3177576621 hasBestOaLocation W31775766211 @default.

• next